Electra Therapeutics, Inc.'s Quiet Period Will Expire on October 28th (NASDAQ:ETRA)

Key Points

• Electra Therapeutics’ quiet period ends October 28, potentially allowing IPO underwriters to begin issuing research coverage after the company’s $350 million offering of 23.33 million shares.
• Analyst sentiment is broadly positive: coverage includes Buy, Outperform, and Overweight ratings, with a consensus Buy rating and $34 price target.
• Directors Orbimed Advisors and Carl L. Gordon each purchased 1.33 million shares at $15, increasing their individual holdings by 35.15%.

Electra Therapeutics' (NASDAQ:ETRA - Get Free Report) quiet period will end on Wednesday, October 28th. Electra Therapeutics had issued 23,333,334 shares in its public offering on September 18th. The total size of the offering was $350,000,010 based on an initial share price of $15.00. During Electra Therapeutics' quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Jefferies Financial Group started coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They issued a "buy" rating and a $32.00 price target for the company. Evercore assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set an "outperform" rating and a $36.00 price objective on the stock. Cantor Fitzgerald assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set an "overweight" rating on the stock. Wall Street Zen upgraded shares of Electra Therapeutics to a "hold" rating in a report on Saturday, September 26th. Finally, TD Cowen began coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set a "buy" rating for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $34.00.

Electra Therapeutics Stock Up 2.3%

ETRA stock opened at $8.81 on Wednesday. Electra Therapeutics has a twelve month low of $8.50 and a twelve month high of $15.50.

Insider Buying and Selling at Electra Therapeutics

In related news, Director Orbimed Advisors Llc purchased 1,333,333 shares of Electra Therapeutics stock in a transaction dated Monday, September 21st. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the acquisition, the director directly owned 5,126,891 shares of the company's stock, valued at $76,903,365. The trade was a 35.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Carl L. Gordon purchased 1,333,333 shares of Electra Therapeutics stock in a transaction dated Monday, September 21st. The shares were bought at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the acquisition, the director directly owned 5,126,891 shares of the company's stock, valued at approximately $76,903,365. This represents a 35.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Electra Therapeutics

Electra Therapeutics, Inc NASDAQ: ETRA is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company's research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body's ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.